AbbVie has entered into a partnership and option-to-license agreement with EvolveImmune Therapeutics, to develop ...

AbbVie (ABBV) Company Description: AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women’s health and ...

AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current ...

EvolveImmune CEO Stephen Bloch said: "This collaboration with AbbVie, a global leader in oncology, offers tremendous validation of the EVOLVE platform and the dedicated and creative work of the ...

AbbVie's strategic acquisitions bolster its pipeline in oncology and neuroscience. Financial performance reflects strong net ...

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer NORTH CHICAGO, Ill.

BeiGene aims to be a next-generation oncology innovator by broadening its drug and pipeline ... BeiGene may lose the lawsuit to AbbVie over Brukinsa and start to pay royalties, which lowers our ...

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer EvolveImmune's ...

The article " High-Yield AbbVie Gains Momentum: A 20% Upside Is in Sight " first appeared on MarketBeat.

With growth catalysts in place, along with dividend payouts, AbbVie is a good medium to long-term buy. Click here to read an ...